Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Bai

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 14, 2005
Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II studyGeorge Fountzilas, Christos Tolis, Anna Kalogera-Fountzila, et al.
BMC Cancer|August 14, 2008
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory studyEvangelia Razis, Evangelos Briasoulis, Eleni Vrettou, et al.
Journal of Cancer Research and Clinical Oncology|March 6, 2014
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximabEvangelia Razis, George Pentheroudakis, George Rigakos, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 14, 2005
Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II studyGeorge Fountzilas, Christos Tolis, Anna Kalogera-Fountzila, et al.
BMC Cancer|August 14, 2008
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory studyEvangelia Razis, Evangelos Briasoulis, Eleni Vrettou, et al.
Journal of Cancer Research and Clinical Oncology|March 6, 2014
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximabEvangelia Razis, George Pentheroudakis, George Rigakos, et al.
Pageof 4